{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-24-000012","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2024-01-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.267879+00:00","generated_at":"2026-06-06T18:23:59.768499+00:00","sec_items":["3.01","5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Zentalis appoints Diana Hausman as CMO, Kyle Rasbach as CBO; receives Nasdaq notice on audit committee","bullets":["Diana Hausman appointed CMO effective Jan 19, 2024; succeeds Carrie Brownstein who stepped down for personal reasons.","Kyle Rasbach appointed CBO; formerly portfolio manager at Eventide Asset Management.","Dr. Hausman resigned from Board and Audit Committee, causing Nasdaq audit committee independence non-compliance.","Company has 180 days (by July 17, 2024) to appoint a third independent director to regain compliance.","Dr. Brownstein receives severance: 10 months base salary + 2023 & prorated 2024 target bonuses, 12 months COBRA."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-24-000012","json":"https://secwatch.observer/filing/0001725160-24-000012.json","markdown":"https://secwatch.observer/filing/0001725160-24-000012.md","text":"https://secwatch.observer/filing/0001725160-24-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000012/0001725160-24-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000012/zntl-20240119.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T18:23:59.768499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34835c52fe","claim":"Diana Hausman was appointed as Chief Medical Officer at Zentalis Pharmaceuticals, Inc..","evidence_excerpt":"On January 25, 2024, Zentalis Pharmaceuticals, Inc. (the “Company” or “Zentalis”) announced that Diana Hausman, M.D., a member of the Company’s Board of Directors (the “Board”), had succeeded Carrie Brownstein, M.D. as Chief Medical Officer of the Company, effective January 19, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000012/0001725160-24-000012-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"51b9ab3e54","claim":"Carrie Brownstein departed as Chief Medical Officer at Zentalis Pharmaceuticals, Inc..","evidence_excerpt":"Dr. Brownstein stepped down for personal reasons.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000012/0001725160-24-000012-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"667dbf4a02","claim":"Diana Hausman resigned as Director at Zentalis Pharmaceuticals, Inc..","evidence_excerpt":"Dr. Hausman resigned from the Board, the Audit Committee of the Board (“Audit Committee”), and the Nominating and Corporate Governance Committee of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000012/0001725160-24-000012-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}